Literature DB >> 32016034

Signals from SABR-COMET time to move on to phase III studies.

Michael T Milano1, Amit K Chowdhry1, Joseph K Salama2, Steven J Chmura3.   

Abstract

Entities:  

Year:  2019        PMID： 32016034      PMCID： PMC6976417          DOI： 10.21037/atm.2019.09.152

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  31 in total

1.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

2.  The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment.

Authors:  Ralph R Weichselbaum
Journal:  J Clin Oncol       Date:  2018-09-27       Impact factor: 44.544

Review 3.  The role of radiation therapy in the curative treatment of metastatic disease.

Authors:  L J Peters; L Milas; G H Fletcher
Journal:  Symp Fundam Cancer Res       Date:  1983

4.  Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).

Authors:  Anthony C Wong; Sydeaka P Watson; Sean P Pitroda; Christina H Son; Lauren C Das; Melinda E Stack; Abhineet Uppal; Go Oshima; Nikolai N Khodarev; Joseph K Salama; Ralph R Weichselbaum; Steven J Chmura
Journal:  Cancer       Date:  2016-05-20       Impact factor: 6.860

5.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Authors:  Piet Ost; Dries Reynders; Karel Decaestecker; Valérie Fonteyne; Nicolaas Lumen; Aurélie De Bruycker; Bieke Lambert; Louke Delrue; Renée Bultijnck; Tom Claeys; Els Goetghebeur; Geert Villeirs; Kathia De Man; Filip Ameye; Ignace Billiet; Steven Joniau; Friedl Vanhaverbeke; Gert De Meerleer
Journal:  J Clin Oncol       Date:  2017-12-14       Impact factor: 44.544

6.  Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years.

Authors:  Khush S Aujla; Alan W Katz; Deepinder P Singh; Paul Okunieff; Michael T Milano
Journal:  Front Oncol       Date:  2019-02-27       Impact factor: 6.244

Review 7.  A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?

Authors:  Faiez Al-Shafa; Andrew J Arifin; George B Rodrigues; David A Palma; Alexander V Louie
Journal:  Front Oncol       Date:  2019-06-21       Impact factor: 6.244

Review 8.  Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment.

Authors:  Hari Menon; Rishab Ramapriyan; Taylor R Cushman; Vivek Verma; Hans H Kim; Jonathan E Schoenhals; Cemre Atalar; Ugur Selek; Stephen G Chun; Joe Y Chang; Hampartsoum B Barsoumian; Quynh-Nhu Nguyen; Mehmet Altan; Maria A Cortez; Stephen M Hahn; James W Welsh
Journal:  Front Immunol       Date:  2019-02-15       Impact factor: 7.561

Review 9.  The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond.

Authors:  Benjamin E Onderdonk; Steven J Chmura
Journal:  Front Oncol       Date:  2019-08-02       Impact factor: 6.244

10.  Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Authors:  Puneeth Iyengar; Zabi Wardak; David E Gerber; Vasu Tumati; Chul Ahn; Randall S Hughes; Jonathan E Dowell; Naga Cheedella; Lucien Nedzi; Kenneth D Westover; Suprabha Pulipparacharuvil; Hak Choy; Robert D Timmerman
Journal:  JAMA Oncol       Date:  2018-01-11       Impact factor: 31.777
View more
  1 in total

Review 1.  Metastasis-directed therapy for oligometastasis and beyond.

Authors:  Thomas H Beckham; T Jonathan Yang; Daniel Gomez; C Jillian Tsai
Journal:  Br J Cancer       Date:  2020-11-18       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.